The ISN has joined the European Kidney Health Alliance (EKHA), a not-for-profit organization dedicated to developing concrete solutions to the challenges posed by Chronic Kidney Disease (CKD) in Europe. Joining the EKHA further enhances ISN’s ability to raise awareness of CKD’s severity and prevalence as a social and economic burden to patients and society within...
As part of the European Kidney Health Alliance (EKHA), ISN supports its Call to Action to: Develop an EU working group (facilitated by EKHA) that will collaborate to design a plan (to be adopted by the EU Commission before the next European elections) to reduce the burden of CKD for patients and society by: Awareness by...
The ISN welcomes the European Commission’s “Pharmaceutical Strategy for Europe,” released on November 25, 2020. Aspects of the strategy’s objectives are reflective of ISN’s vision of equitable access to kidney health and include: Re-thinking policies to stimulate innovation in areas of need, and patient-centered, health system-oriented pharmaceutical innovation to address long-term care settings. Investing in research and...
The ISN is currently liaising with the European Union (EU) and African, Caribbean, and Pacific (ACP) Group of States representatives to ensure that a forthcoming partnership agreement between these blocs promotes UHC in all ACP countries, particularly regarding optimal health care for patients living with kidney diseases. The Cotonou Agreement, signed in 2000 by the...
